跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
QARZIBA dinutuximab beta 4.5 mg/mL concentrate for solution for infusion, 20 mg/4.5 mL vial - TGA Drug Approval Details
Approvals
/
TGA
/
QARZIBA dinutuximab beta 4.5 mg/mL concentrate for solution for infusion, 20 mg/4.5 mL vial
Approved
STANDARD
QARZIBA dinutuximab beta 4.5 mg/mL concentrate for solution for infusion, 20 mg/4.5 mL vial
Recordati Rare Diseases Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
9d60dcaef16b9824
Company
Recordati Rare Diseases Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
9d60dcaef16b9824
Product Name
QARZIBA dinutuximab beta 4.5 mg/mL concentrate for solution for infusion, 20 mg/4.5 mL vial
Artg Id
321016
Artg Name
QARZIBA dinutuximab beta 4.5 mg/mL concentrate for solution for infusion, 20 mg/4.5 mL vial
Sponsor
Recordati Rare Diseases Australia Pty Ltd
Company Detail Path
/organization/recordati-rare-diseases-australia-pty-ltd
Artg Date
2020-04-02
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/3f0015e21d9978b26d327bbcf0d690e5.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/490c31e5e3bf099ce43b2ba243a41153.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
9d60dcaef16b9824
Type
Standard
Back to TGA Approvals